8-K: MetaVia Reports Strong Q2, Advances Key Drug Trials

MetaVia Inc. announced positive Q2 2025 financial results and significant clinical progress for its cardiometabolic drug candidates, extending its cash runway into 2026.

Summary

• Dosed the first patient in the 8-week 48 mg multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, an obesity treatment.
• Top-line data from the 8-week 48 mg DA-1726 cohort is expected in the fourth quarter of 2025.
• Previous 32 mg DA-1726 data showed an average 4.3% weight loss (max 6.3%) by Day 26, 83% of patients reporting early satiety, and an average 1.6-inch waist circumference decrease by Day 33.
• DA-1726 at 32 mg also reduced fasting glucose by up to 18 mg/dL without hypoglycemia and demonstrated favorable cardiovascular safety with mild, transient, and infrequent GI side effects.
• Signed an AI-driven collaboration with Syntekabio to explore additional indications for DA-1241 beyond MASH.
• Presented new preclinical data on DA-1241 at the ADA's 85th Scientific Sessions, showing synergistic benefits with Efruxifermin in reducing liver fat, inflammation, and fibrosis in a MASH mouse model.
• Phase 2a results for DA-1241 presented at EASL Congress 2025 showed a significant decrease in plasma ALT levels (mean reduction of 22.8 U/L) and an improvement in Controlled Attenuation Parameter (CAP) Score by 23.0 dB/m.
• Net loss for the second quarter ended June 30, 2025, was $4.0 million, or $0.26 per basic and diluted share, a significant reduction from $10.1 million, or $1.85 per share, in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $7.7 million, or $0.60 per share, compared to $16.8 million, or $3.19 per share, for the same period in 2024.
• Research and Development (R&D) Expenses decreased to $2.3 million in Q2 2025 from $8.1 million in Q2 2024.
• Total Operating Expenses decreased to $4.3 million in Q2 2025 from $10.1 million in Q2 2024.
• Cash balance was $17.6 million as of June 30, 2025, up from $16.0 million as of December 31, 2024.
• The company expects its cash position to fund operations into 2026.

Sentiment

Score: 8

Explanation: The filing conveys strong positive sentiment due to significant clinical advancements for both lead drug candidates, favorable safety and efficacy profiles, a substantial reduction in net loss, and an extended cash runway. Strategic collaborations further enhance future prospects, indicating robust progress and financial stability.

Positives

• Positive clinical data for DA-1726 (obesity) at 32 mg dose, demonstrating significant weight loss (average 4.3%, max 6.3%), improved glucose control, favorable cardiovascular safety, and better tolerability than current GLP-1 therapies.
• Extension of the DA-1726 48 mg cohort to 8 weeks aims to evaluate longer-term efficacy and safety, and explore the maximum tolerated dose without titration.
• Promising preclinical and Phase 2a data for DA-1241 (MASH), showing synergistic benefits with Efruxifermin and improvements in key liver health markers (ALT, CAP, FAST, NIS-4).
• Strategic AI collaboration with Syntekabio to identify new, high-potential indications for DA-1241, leveraging advanced drug discovery technology.
• Significant reduction in net loss for Q2 2025 to $4.0 million from $10.1 million in Q2 2024, indicating improved financial efficiency.
• Cash balance of $17.6 million as of June 30, 2025, is expected to fund operations into 2026, providing a strong financial runway.
• Successful private placement in May 2025 raised $10.0 million in gross proceeds, strengthening the company's capital position.

Risks

• Ability to execute on commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions.
• Ability to obtain regulatory approval through the development steps of current and future product candidates.
• Ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results.
• Cooperation of contract manufacturers, clinical study partners, and others involved in product development.
• Potential negative interactions between product candidates and any other products with which they are combined for treatment.
• Ability to initiate and complete clinical trials on a timely basis.
• Ability to recruit subjects for clinical trials.
• Whether clinical trial results are consistent with the results of pre-clinical and previous clinical trials.
• Impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions.
• Effects of changes in applicable laws or regulations.
• Effects of changes to stock price on the terms of the license agreement and any future fundraising.

Future Outlook

Data from the 8-week 48 mg MAD cohort of DA-1726 for obesity is expected in the fourth quarter of 2025. The company is currently working to schedule an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for DA-1241. Early insights from the AI-driven collaboration with Syntekabio are anticipated later this year. The company's cash position is expected to fund operations into 2026.

Management Comments

• "During the second quarter and recently, we continued to make significant progress advancing the clinical development of our two next-generation cardiometabolic assets."
• "A key milestone was the dosing of the first patient in the 48 mg multiple ascending dose (MAD) Phase 1 trial of DA-1726..."
• "Previously reported clinical data from the 32 mg dose cohort highlighted DA-1726s best-in-class potential, demonstrating a compelling safety and tolerability profile without the need for dose titration."
• "We expect the 32 mg dose will serve as the starting point for future clinical trials."
• "Following our successful private placement for aggregate gross proceeds of $10.0 million in May, we remain well-capitalized to reach this milestone, with our runway now extended into 2026."
• "The new data further underscores the potential of combining DA-1241 with an FGF21 analogue, such as Efruxifermin."
• "We believe this well-tolerated oral candidate can address significant unmet needs and look forward to early insights later this year."

Industry Context

MetaVia operates in the highly competitive and rapidly evolving cardiometabolic disease space, addressing significant unmet medical needs in obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its DA-1726, a dual GLP1R/GCGR agonist, aims to differentiate itself from existing GLP-1 therapies by potentially offering superior weight loss and metabolic benefits with improved tolerability. DA-1241, a first-in-class oral GPR119 agonist for MASH, positions the company in a field increasingly focused on combination therapies to tackle the complex pathology of liver diseases. The collaboration with Syntekabio highlights the growing trend of integrating AI into drug discovery to accelerate development and identify new therapeutic applications.

Comparison to Industry Standards

• DA-1726 demonstrated 'best-in-class potential' for weight loss, glucose control, and waist reduction, suggesting superior efficacy compared to some existing treatments.
• DA-1726's GI side effects were described as 'mild, transient, and infrequent,' suggesting 'better tolerability than current GLP-1 therapies,' which often face challenges with GI adverse events.
• DA-1241 is highlighted as a 'first-in-class oral GPR119 agonist,' indicating a novel mechanism of action compared to other MASH candidates.
• The synergistic benefits of combining DA-1241 with an FGF21 analogue like Efruxifermin align with the industry's shift towards multi-modal approaches for complex diseases like MASH, where single-target therapies have shown limited success.

Related Party Transactions

• Closed a private placement offering in May 2025 with Dong-A ST, a related party, and Dong-A Socio Holdings Co., Ltd., the parent company of Dong-A ST, for gross proceeds of $10.0 million.
• Included in direct R&D costs were expenses totaling $1.3 million for the three months ended June 30, 2025, and $2.4 million for the six months ended June 30, 2025, related to investigational drug manufacturing, non-clinical and preclinical costs incurred under the Shared Services Agreement with Dong-A ST (related party).

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical progress, improved financial performance (reduced net loss), extended cash runway, and strategic collaborations, potentially leading to increased shareholder value.
• Patients: Potential for new, effective, and well-tolerated treatments for obesity and MASH, addressing significant unmet medical needs.
• Employees: Continued progress in clinical development and strategic partnerships suggest stability and ongoing opportunities within the company.
• Creditors: Improved cash position and reduced burn rate enhance the company's financial stability and ability to meet obligations.

Next Steps

• Report data from the 8-week 48 mg MAD cohort of DA-1726 in the fourth quarter of 2025.
• Schedule an end-of-Phase 2 meeting with the FDA for DA-1241.
• Anticipate early insights from the research collaboration with Syntekabio later this year.

Key Dates

Recommendation

The company reported a substantial reduction in net loss and a strengthened cash position, extending its operational runway into 2026. Both lead drug candidates, DA-1726 for obesity and DA-1241 for MASH, demonstrated highly promising clinical and preclinical data, with DA-1726 showing 'best-in-class potential' and DA-1241 exhibiting synergistic effects. The strategic AI collaboration further de-risks and expands the potential of DA-1241. Upcoming data readouts and regulatory meetings represent significant catalysts. The combination of strong clinical validation, improved financials, and strategic foresight positions MetaVia for significant upside.

Keywords

Biotechnology, Cardiometabolic diseases, Obesity, MASH, GLP-1 receptor agonist, Glucagon receptor agonist, GPR119 agonist, Clinical trials, Drug development, Financial results, SEC filing, Biopharma, AI drug discovery